Cargando…

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers

Targeting defects in metabolism is an underutilized strategy for the treatment of cancer. Arginine auxotrophy resulting from the silencing of argininosuccinate synthetase 1 (ASS1) is a common metabolic alteration reported in a broad range of aggressive cancers. To assess the metabolic effects that a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremer, Jeff Charles, Prudner, Bethany Cheree, Lange, Sara Elaine Stubbs, Bean, Gregory Richard, Schultze, Matthew Bailey, Brashears, Caitlyn Brook, Radyk, Megan DeAnna, Redlich, Nathan, Tzeng, Shin-Cheng, Kami, Kenjiro, Shelton, Laura, Li, Aixiao, Morgan, Zack, Bomalaski, John Stephen, Tsukamoto, Takashi, McConathy, Jon, Michel, Loren Scott, Held, Jason Matthew, Van Tine, Brian Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840045/
https://www.ncbi.nlm.nih.gov/pubmed/28122247
http://dx.doi.org/10.1016/j.celrep.2016.12.077
Descripción
Sumario:Targeting defects in metabolism is an underutilized strategy for the treatment of cancer. Arginine auxotrophy resulting from the silencing of argininosuccinate synthetase 1 (ASS1) is a common metabolic alteration reported in a broad range of aggressive cancers. To assess the metabolic effects that arise from acute and chronic arginine starvation in ASS1-deficient cell lines, we performed metabolite profiling. We found that pharmacologically induced arginine depletion causes increased serine biosynthesis, glutamine anaplerosis, oxidative phosphorylation, and decreased aerobic glycolysis, effectively inhibiting the Warburg effect. The reduction of glycolysis in cells otherwise dependent on aerobic glycolysis is correlated with reduced PKM2 expression and phosphorylation and upregulation of PHGDH. Concurrent arginine deprivation and glutaminase inhibition was found to be synthetic lethal across a spectrum of ASS1-deficient tumor cell lines and is sufficient to cause in vivo tumor regression in mice. These results identify two synthetic lethal therapeutic strategies exploiting metabolic vulnerabilities of ASS1-negative cancers.